Tools   Select Another Resource Report Type

http://www.sbur.org/

The Society for Basic Urologic Research (SBUR) is a society of scientists whose expertise includes the study of urologic cancers (prostate, bladder, kidney, testis, penis), the biology of prostate growth, kidney and bladder function, autoimmune urologic diseases, infectious diseases, neuro-urologic diseases, male reproductive biology, infertility and erectile dysfunction. Members include molecular biologists, immunologists, epidemiologists, oncologists, biochemists and clinical urologic scientists. SBUR members serve on a wide variety of advisory panels, study sections, editorial boards and in the pharmaceutical industry. The SBUR organizes two annual meetings to share new findings at a multidisciplinary level, to promote interaction among members and other interested scientists and to highlight new areas of research and funding opportunities. The Society was organized to address the following: * To provide a forum for the presentation and discussion of basic scientific topics related to urology * To develop educational forums concerning scientific advancements related to the field of urology * To promote collaborative investigations among member scientists with an emphasis on the interchange of expertise among clinical and basic scientists * To promote the communication and interests of urologic disease investigators with national funding agencies, industry representatives and academic institutions with regards to urology related research * To serve as a resource for research information and expertise to clinical urologists through the American Urological Association

Proper citation: SBUR - Society for Basic Urologic Research (RRID:SCR_005856) Copy   

•   Source: SciCrunch Registry

http://www.nncc-exam.org/

Organization that established credentialing mechanisms to promote patient safety and to improve the quality of care provided to nephrology patients. There is a diversity of examinations providing the opportunity for certification at various levels of education, experience, and areas of practice within nephrology nursing. All of the certification examinations are endorsed by American Nephrology Nurses'''' Association (ANNA). The Commission recognizes the value of education, administration, research, and clinical practice in fostering personal and professional growth and currently provides six examinations to validate clinical performance: * The Certified Dialysis Nurse examination * The Certified Dialysis LPN/LVN examination * The Certified Nephrology Nurse examination * The Certified Clinical Hemodialysis Technician * The Certified Clinical Hemodialysis Technician - Advanced * The Certified Nephrology Nurse - Nurse Practitioner

Proper citation: Nephrology Nursing Certification Commission (RRID:SCR_003994) Copy   

•   Source: SciCrunch Registry

https://glomcon.org

Consortium to bring together clinicians, pathologists, researchers, and biotech innovators to create scalable network of stakeholders interested in helping patients with glomerular kidney disease. Makes collective expertise of its members available for discussion of individual cases, provides infrastructure for biomarker studies, enables genomic research, and facilitates clinical trials.

Proper citation: Glomerular Disease Study & Trial Consortium (RRID:SCR_017264) Copy   

•   Source: SciCrunch Registry

http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM285010.pdf

Urinary kidney biomarkers, Clusterin and Renal Papillary Antigen-1 (RPA-1), that sponsors may use to determine more conservative NOAELs for estimating starting doses in the initial human clinical trial of a drug that displays nonclinical nephrotoxicity as determined by histopathology. When tested with a limited number of nephrotoxic compounds, the Receiver Operating Characteristic (ROC) analyses showed that urinary clusterin and renal papillary antigen-1 (RPA-1) have better sensitivity and specificity than BUN and creatinine for the detection of specific kidney pathologies in male rats. Clusterin and RPA-1 provide additional and complementary information to BUN, serum creatinine (sCr), and histopathology for the detection of acute drug-induced nephrotoxicity in safety assessment studies.

Proper citation: ILSI HESI Drug-induced Nephrotoxicity Biomarkers (RRID:SCR_003716) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00143949

Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained.

Proper citation: Renin Angiotensin System Study (RRID:SCR_013385) Copy   

•   Source: SciCrunch Registry

http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/

A prospective observational national cohort study poised to make fundamental insights into the epidemiology, management, and outcomes of chronic kidney disease (CKD) in adults with intended long-term follow up. The major goals of the CRIC Study are to answer two important questions: * Why does kidney disease get worse in some people, but not in others? * Why do persons with kidney disease commonly experience heart disease and stroke? The CRIC Scientific and Data Coordinating Center at Penn receives data and provides ongoing support for a number of Ancillary Studies approved by the CRIC Cohort utilizing both data collected about CRIC study participants as well as their biological samples. The CRIC Study has enrolled over 3900 men and women with CKD from 13 recruitment sites throughout the country. Following this group of individuals over the past 10 years has contributed to the knowledge of kidney disease, its treatment, and preventing its complications. The NIDDKwill be extending the study for an additional 5 years, through 2018. An extensive set of study data is collected from CRIC Study participants. With varying frequency, data are collected in the domains of medical history, physical measures, psychometrics and behaviors, biomarkers, genomics/metabolomics, as well as renal, cardiovascular and other outcomes. Measurements include creatinine clearance and iothalamate measured glomerular filtration rate. Cardiovascular measures include blood pressure, ECG, ABI, ECHO, and EBCT. Clinical CV outcomes include MI, ischemic heart disease-related death, acute coronary syndromes, congestive heart failure, cerebrovascular disease, peripheral vascular disease, and composite outcomes. The CRIC Study has delivered in excess of 150,000 bio-samples and a dataset characterizing all 3939 CRIC participants at the time of study entry to the NIDDKnational repository. The CRIC Study will also be delivering a dataset to NCBI''''s Database for Genotypes and Phenotypes.

Proper citation: Chronic Renal Insufficiency Cohort Study (RRID:SCR_009016) Copy   

•   Source: SciCrunch Registry

http://www.medibeacon.com/preclinical/

Software used to analyze glomerular filtration rate (GFR) measurement from MediBeacon GFR monitor. It is used with the Transdermal Continuous Renal Function Monitor.

Proper citation: MediBeacon Studio Software (RRID:SCR_016252) Copy   

•   Source: SciCrunch Registry

https://hirnetwork.org/consortium/cbds

Consortium that is an independent research initiative of the Human Research Information Network (HIRN). It is using human tissues to discover highly specific biomarkers of beta cell injury in asymptomatic T1D and developing strategies to stop beta cell destruction early in the disease process.

Proper citation: HIRN Consortium on Beta Cell Death and Survival (RRID:SCR_016198) Copy   

•   Source: SciCrunch Registry

http://sharpentrials.com/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Organization that uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Their combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Their efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug''s mechanism of action.

Proper citation: ClinMet (RRID:SCR_003979) Copy   

•   Source: SciCrunch Registry

http://pepr.cnmcresearch.org/

An experiment in web-database access to large multi-dimensional data sets using a standardized experimental platform to determine if the larger scientific community can be given simple, intuitive, and user-friendly web-based access to large microarray data sets. All data in PEPR is also available via NCBI GEO. The structure and goals of PEPR differ from other mRNA expression profiling databases in a number of important ways. * The experimental platform in PEPR is standardized, and is an Affymetrix - only database. All microarrays available in the PEPR web database should ascribe to quality control and standard operating procedures. A recent publication has described the QC/SOP criteria utilized in PEPR profiles ( The Tumor Analysis Best Practices Working Group 2004 ). * PEPR permits gene-based queries of large Affymetrix array data sets without any specialized software. For example, a number of large time series projects are available within PEPR, containing 40-60 microarrays, yet these can be simply queried via a dynamic web interface with no prior knowledge of microarray data analysis. * Projects in PEPR originate from scientists world-wide, but all data has been generated by the Research Center for Genetic Medicine, Children''''s National Medical Center, Washington DC. Future developments of PEPR will allow remote entry of Affymetrix data ascribing to the same QC/SOP protocols. They have previously described an initial implementation of PEPR, and a dynamic web-queried time series graphical interface ( Chen et al. 2004 ). A publication showing the utility of PEPR for pharmacodynamic data has recently been published ( Almon et al. 2003 ).

Proper citation: Public Expression Profiling Resource (RRID:SCR_007274) Copy   

•   Source: SciCrunch Registry

http://netbio.bgu.ac.il/tissuenet/

Database of human tissue protein-protein interactions (PPIs) that associates each interaction with human tissues that express both pair mates. This was achieved by integrating current data of experimentally detected PPIs with extensive data of gene and protein expression across 16 main human tissues. Users can query TissueNet using a protein and retrieve its PPI partners per tissue, or using a PPI and retrieve the tissues expressing both pair mates. The graphical representation of the output highlights tissue-specific and tissue-wide PPIs. Thus, TissueNet provides a unique platform for assessing the roles of human proteins and their interactions across tissues.

Proper citation: TissueNet - The Database of Human Tissue Protein-Protein Interactions (RRID:SCR_002052) Copy   

•   Source: SciCrunch Registry

http://nmri.niddk.nih.gov/

Communication network of current and potential biomedical research investigators and technical personnel from traditionally under-served communities: African American, Hispanic American, American Indian, Alaskan Native, Native Hawaiian, and other Pacific Islanders. The major objective of the network is to encourage and facilitate participation of members of underrepresented racial and ethnic minority groups in the conduct of biomedical research in the fields of diabetes, endocrinology, metabolism, digestive diseases, nutrition, kidney, urologic and hematologic diseases. A second objective is to encourage and enhance the potential of the underrepresented minority investigators in choosing a biomedical research career in these fields. An important component of this network is promotion of two-way communications between network members and the NIDDK.

Proper citation: Network of Minority Health Research Investigators (RRID:SCR_006589) Copy   

•   Source: SciCrunch Registry

http://www.biobanks.se/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 6th, 2022. The biobank comprises paraffin blocks of surgical and autopsy tissue samples and corresponding histological slides as well as cytological material consisting of slides of vaginal smears, fine needle aspiration biopsies and exfoliative cytological material. The tissue samples date back until 1944 and most of the cytological samples until 1970. A subunit of the bank constitutes the National Tissue Microarray Centre. This center is supported by SWEGENE with the purpose to organize and construct tissue microarrays (TMA:s) for high throughput molecular pathology research on various kinds of tumors and other diseases. By linking the TMA.s to long-term and complete clinical follow-up data, prognostic and predictive studies will be facilitated. Biobank content: * Approximately 2,4 million paraffin blocks of surgical tissue specimens, * 1,1 million paraffin blocks of tissue samples from autopsies, * 3,8 million histological slides and * 1,6 million cytology slides. At present, the Tissue Microarray Centre includes: * A consecutive series of all invasive breast cancers (n=600) diagnosed in Malmo between 1988 and 1992. * All incident breast cancers within the Malmo Diet and Cancer cohort (n=400). * A subgroup of 600 pre-menopausal primary breast cancers within the nationwide, population-based randomized tamoxifen trial SBII:2. * 180 primary breast cancers from post-menopausal women included in a similar study. * A set of 120 extremely well characterized primary breast cancer samples with a clinical follow-up of 10 years. More than 40 relevant tumor biological parameters have been recorded in this material and it is therefore useful for a first screening of a marker in order to identify associations to other gene products. * 350 renal cell carcinomas (In collaboration with NUS). We provide researchers with state-of-the-art population based tissue microarrays with long-term and complete follow-up data on survival and treatment. With the TMA-technology, valuable biobank material will be preserved, allowing high throughput in-situ analyses of various tumors and other diseases with a minimal waste of tissue.

Proper citation: UMAS University Hospital - Biobanks of the Department of Clinical Pathology and Cytology (RRID:SCR_005957) Copy   

•   Source: SciCrunch Registry

http://www.renalmd.org/

An association representing and serving nephrology practitioners in the United States whose members are committed to improving the care of patients with chronic kidney disease (CKD) and related disorders. RPA educates policymakers about issues that affect both patients and nephrology practices. They also work with the Centers for Medicare & Medicaid Services (CMS) on regulatory policies. (Adapted from Wikipedia) Programs focus in the areas of practice management, public policy and quality patient care. They provide timely and relevant programs along with current nephrology tools and resources to make certain members maintain their highest level of professional satisfaction.

Proper citation: Renal Physicians Association (RRID:SCR_004048) Copy   

•   Source: SciCrunch Registry

http://cellfinder.de/about/ontology/

Structured vocabulary to organize cell-associated data and to place these data in clearly defined semantic relations to other biological facts. It describes cell types, their properties and origin and links this information to other existing ontologies like the Cell Ontology (CL), Foundational Model of Anatomy (FMA), Gene Ontology (GO), Mouse Anatomy and others using the top-level ontology BioTop.

Proper citation: CELDA Ontology (RRID:SCR_001601) Copy   

•   Source: SciCrunch Registry

http://tvmouse.ucdavis.edu/anatomy/

Access to Quicktime movies of histologic mouse anatomy including heart / lung, kidney, mammary gland, lymph node, prostate, spleen, liver, salivary glands, and 3-D wire model based on MRI sections; a Quicktime mouse radiographic atlas of skeletal anatomy containing a series of radiographic images with color overlays and labels; and a table containing a comparison between mouse and human anatomy. Special topics include the virtual necroscopy. Anatomic systems cover the central nervous system, male genital-urinary tract, female genital-urinary tract, mammary, kidney, skeletal, cardiovascular, gastrointestinal, and respiratory systems. The pathology and imaging section includes anatomy, histology, comparative imaging, physiology, pathology, comparative mammary, comparative prostate, GEM, and an image archive. These pages were put together as a pilot demonstration by Dr. Robert Cardiff, UCD Center for Comparative Medicine with the collaboration of Dr. Michael Paulus, Oak Ridge National Laboratories,MicroCat Group, Dr. Allan Johnson, Duke University Center for In Vivo Microscopy, and Drs. Steve Griffey, Gary Henderson and Tom Jue, University of California, Davis. This is a work in progress and for demonstration purposes.

Proper citation: Visible Mouse Anatomy (RRID:SCR_001603) Copy   

•   Source: SciCrunch Registry

http://www.unos.org/

United Network for Organ Sharing (UNOS) is the private, non-profit organization that manages the nation''s organ transplant system under contract with the federal government. UNOS is involved in many aspects of the organ transplant and donation process: * Managing the national transplant waiting list, matching donors to recipients 24 hours a day, 365 days a year. * Maintaining the database that contains all organ transplant data for every transplant event that occurs in the U.S. * Bring together members to develop policies that make the best use of the limited supply of organs and give all patients a fair chance at receiving the organ they need, regardless of age, sex, ethnicity, religion, lifestyle or financial/social status. * Monitoring every organ match to ensure organ allocation policies are followed. * Provides assistance to patients, family members and friends. * Educates transplant professionals about their important role in the donation and transplant processes. * Educating the public about the importance of organ donation. UNOS was first awarded the national Organ Procurement and Transplantation Network (OPTN) contract in 1986 by the U.S. Department of Health and Human Services. UNOS continues as the only organization ever to operate the OPTN. As part of the OPTN contract, UNOS has: * established an organ sharing system that maximizes the efficient use of deceased organs through equitable and timely allocation * established a system to collect, store, analyze and publish data pertaining to the patient waiting list, organ matching, and transplants * informed, consulted and guided persons and organizations concerned with human organ transplantation in order to increase the number of organs available for transplantation

Proper citation: UNOS - United Network for Organ Sharing (RRID:SCR_004976) Copy   

•   Source: SciCrunch Registry

http://cellfinder.de/

Database of mapped validated gene and protein expression, phenotype and images related to cell types. The data allow characterization and comparison of cell types and can be browsed by using the body browser and by searching for cells or genes. All cells are related to more complex systems such as tissues, organs and organisms and arranged according to their position in development. CellFinder provides long-term data storage for validated and curated primary research data and provides additional expert-validation through relevant information extracted from text. Operated under the Open Source/Access model, community and scientific networking applications will allow users to store and retrieve their data and to explore cells and their interactions on singular and complex resolution levels. The involvement of stem cell registries and banks will allow direct access to selected cells. The set up the stem cell data repository will involve three lines of action: * the acquisition of scientific data and contents * the standardized description of this data, its organization with the help of ontologies and technical implementation * the integration of existing sources/logistics and to ensure sustainable long-term operation

Proper citation: CellFinder (RRID:SCR_006598) Copy   

•   Source: SciCrunch Registry

http://www.diabetes.niddk.nih.gov/

Information dissemination service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established to increase knowledge and understanding about diabetes among patients, health care professionals, and the general public: online, in booklets and fact sheets, by email, and over the phone. To carry out this mission, NDIC works closely with NIDDK''''s Diabetes Research and Training Centers; the National Diabetes Education Program (NDEP); professional, patient, and voluntary associations; Government agencies; and State health departments to identify and respond to informational needs about diabetes and its management. NDIC provides the following informational products and services: * Response to inquiries about diabetes, ranging from information about available patient and professional education materials to statistical data. By phone (8:30 a.m. to 5 p.m. eastern time, M-F), fax, mail, and email. * Publications about diabetes, provided free of copyright, in varying reading levels. Available online or as booklets and brochures. NDIC also sends publications to health fairs and community events. * Referrals to health professionals through the National Library of Medicine''''s MEDLINEplus includes a consumer-friendly listing of organizations that will assist you in your search for physicians and other health professionals. * Exhibits at professional meetings specific to diabetes, as well as cross-cutting professional meetings. NDIC exhibits at 12 professional meetings, each year, including American Diabetes Association Postgraduate Course, American College of Physicians, CDC Diabetes Translation Conference, American Academy of Physician Assistants, American Diabetes Association, American Association of Diabetes Educators, and American Dietetic Association.

Proper citation: National Diabetes Information Clearinghouse (RRID:SCR_006702) Copy   

•   Source: SciCrunch Registry

http://www.lef.org/bloodtest

Blood testing is the single most important preventive tool you can use to help head off health problems. Life Extension makes it possible to take advantage of that tool at a fraction of the cost commercial blood labs charge. Get a picture of your overall health. Identify potential disease risks. Test for specific problems with comprehensive blood test panels and individualized tests like these: * Male and Female Comprehensive Panels * Cardiac Risk Factors * Vitamin Deficiencies * Hormone and Thyroid Panels * Metabolic and Chemistry Profiles

Proper citation: Life Extension: Laboratory and Blood Testing Services (RRID:SCR_007167) Copy   

•   Source: SciCrunch Registry